BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
Status:
Completed
Trial end date:
2016-12-28
Target enrollment:
Participant gender:
Summary
This phase I trial will determine the Maximum Tolerated Dose (MTD) of BKM120 when given
together with fulvestrant in treating postmenopausal patients with estrogen receptor-positive
(ER+) stage IV breast cancer. The toxicity profile of this combination therapy will also be
described. Inhibition of PI3K by BKM120 may enhance programmed cell death (apoptosis) in
estrogen receptor positive (ER+) breast cancer cells. Giving fulvestrant together with BKM
120 may enhance this apoptotic effect, providing a novel therapeutic strategy for patients
with metastatic ER+ breast cancer.